Management of Renal Angiomyolipomas in Tuberous Sclerosis Complex: A Case Report and Literature Review

Overview

Journal J Clin Med

Specialty General Medicine

Date 2022 Oct 27

PMID 36294405

Authors

Mitchell Hunter-Dickson

Patrick Wu

Akshay Athavale

Amanda Ying Wang

Affiliations

Soon will be listed here.

Abstract

We report a case of misdiagnosed tuberous sclerosis complex (TSC) in a patient without TSC gene variant presenting with bilateral renal angiomyolipomas and seizures in the context of strong family history of polycystic kidney disease. Clinical diagnosis of tuberous sclerosis complex was made and treatment with everolimus reduced size of renal angiomyolipomas. In this case, report we discuss the association between tuberous sclerosis complex and polycystic kidney disease and novel treatment for TSC.

Citing Articles

A Rare Case of Renal Angiomyolipoma and Polycystic Kidney Disease in a Patient with Tuberous Sclerosis.

Shah R, Venkata Renuka I, Gundapaneni T, Shah H Cureus. 2024; 16(6):e63031.

PMID: 39050299 PMC: 11268081. DOI: 10.7759/cureus.63031.

A 28-year-old patient with tuberous sclerosis associated with renal angiomyolipoma:A rare case report and literature review.

Haydar H, Sleiay M, Alqreea M, Almohamed A, Alrajab D, Alsaleh M Urol Case Rep. 2024; 54:102705.

PMID: 38827532 PMC: 11143435. DOI: 10.1016/j.eucr.2024.102705.

References

Overwater I, Rietman A, Van Eeghen A, De Wit M . Everolimus for the treatment of refractory seizures associated with tuberous sclerosis complex (TSC): current perspectives. Ther Clin Risk Manag. 2019; 15:951-955. PMC: 6666377. DOI: 10.2147/TCRM.S145630. View

French J, Lawson J, Yapici Z, Ikeda H, Polster T, Nabbout R . Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet. 2016; 388(10056):2153-2163. DOI: 10.1016/S0140-6736(16)31419-2. View

Cai Y, Guo H, Wang W, Li H, Sun H, Shi B . Assessing the outcomes of everolimus on renal angiomyolipoma associated with tuberous sclerosis complex in China: a two years trial. Orphanet J Rare Dis. 2018; 13(1):43. PMC: 5870799. DOI: 10.1186/s13023-018-0781-y. View

de Wit D, Schneider T, Moes D, Roozen C, den Hartigh J, Gelderblom H . Everolimus pharmacokinetics and its exposure-toxicity relationship in patients with thyroid cancer. Cancer Chemother Pharmacol. 2016; 78(1):63-71. PMC: 4921118. DOI: 10.1007/s00280-016-3050-6. View

Franz D, Belousova E, Sparagana S, Bebin E, Frost M, Kuperman R . Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2012; 381(9861):125-32. DOI: 10.1016/S0140-6736(12)61134-9. View

Dillman J, Trout A, Smith E, Towbin A . Hereditary Renal Cystic Disorders: Imaging of the Kidneys and Beyond. Radiographics. 2017; 37(3):924-946. DOI: 10.1148/rg.2017160148. View

Davies M, Saxena A, Kingswood J . Management of everolimus-associated adverse events in patients with tuberous sclerosis complex: a practical guide. Orphanet J Rare Dis. 2017; 12(1):35. PMC: 5311836. DOI: 10.1186/s13023-017-0581-9. View

Franz D, Belousova E, Sparagana S, Bebin E, Frost M, Kuperman R . Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study. PLoS One. 2016; 11(6):e0158476. PMC: 4924870. DOI: 10.1371/journal.pone.0158476. View

Tyburczy M, Dies K, Glass J, Camposano S, Chekaluk Y, Thorner A . Mosaic and Intronic Mutations in TSC1/TSC2 Explain the Majority of TSC Patients with No Mutation Identified by Conventional Testing. PLoS Genet. 2015; 11(11):e1005637. PMC: 4634999. DOI: 10.1371/journal.pgen.1005637. View

10.

Henske E, Jozwiak S, Kingswood J, Sampson J, Thiele E . Tuberous sclerosis complex. Nat Rev Dis Primers. 2016; 2:16035. DOI: 10.1038/nrdp.2016.35. View

11.

Bissler J, Kingswood J, Radzikowska E, Zonnenberg B, Frost M, Belousova E . Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2013; 381(9869):817-24. DOI: 10.1016/S0140-6736(12)61767-X. View

12.

Northrup H, Aronow M, Bebin E, Bissler J, Darling T, de Vries P . Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations. Pediatr Neurol. 2021; 123:50-66. DOI: 10.1016/j.pediatrneurol.2021.07.011. View

13.

Sehgal V, Bajwa S, Bajaj A . New orally active anticoagulants in critical care and anesthesia practice: the good, the bad and the ugly. Ann Card Anaesth. 2013; 16(3):193-200. DOI: 10.4103/0971-9784.114244. View

14.

Bissler J, Kingswood J, Radzikowska E, Zonnenberg B, Frost M, Belousova E . Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial. Nephrol Dial Transplant. 2015; 31(1):111-9. DOI: 10.1093/ndt/gfv249. View

15.

Crino P, Nathanson K, Henske E . The tuberous sclerosis complex. N Engl J Med. 2006; 355(13):1345-56. DOI: 10.1056/NEJMra055323. View

16.

Borkowska J, Schwartz R, Kotulska K, Jozwiak S . Tuberous sclerosis complex: tumors and tumorigenesis. Int J Dermatol. 2010; 50(1):13-20. DOI: 10.1111/j.1365-4632.2010.04727.x. View